|drug1389||HOME-CoV rule implementation Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact severity of COVID-19 positive and negative subjects and assessment of predictors for post COVID-19 complications. In Phase 2, 2700 subjects with COVID-19 positive test will be studied in the intervention group comparing ECL-19 vs placebo with primary end point of hospital admission assessment. Treatment strategy for PCR positive COVID-19 subjects in the registry who are in Stage I of the disease process with ECL-19 drug compared to placebo in reducing hospital admissions
Description: Measure COVID-19 infection risk score based on PCR Positive TestMeasure: Predictors of post COVID-19 complications and predictors of hospitalization Time: 1 Day
Description: Measure COVID-19 infection risk score based on health symptomsMeasure: Health symptom score Time: 1 Day
Description: Measure COVID-19 infection high risk score based on vital signs SpO2 <94%Measure: Vital signs SpO2 score Time: 1 Day
Description: Measure COVID-19 infection high risk score based on Height 0.15 meters and Weight of 122 KgsMeasure: Vital signs BMI score of 40 kg/m2 Time: 1 Day
Description: Measure COVID-19 infection high risk score based on chronic illness response; Yes on uncontrolled Asthma, COPD, Hypertension, T2DMMeasure: Chronic Illness score Time: 1 Day
Description: Measure COVID-19 infection risk score based on mental health assessment for DepressionMeasure: Mental health assessment high score >11 on PHQ9 Depression score Time: 1 Day
Description: Measure COVID-19 infection risk score based on mental health assessment for AnxietyMeasure: Mental health assessment high score >11 on GAD 7 Anxiety score Time: 1 Day
Description: Measure hospital admissions in PCR positive COVID 19 subjects within 48 hours who are in Stage I of the disease processMeasure: Evaluate a treatment strategy with ECL-19 Time: 1 Day
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports